Summary: A new study from the University of Florida links common glucosamine supplements to faster cognitive decline in people with vulnerable brains. Researchers combined a 12-year artificial-intelligence audit of electronic health records with advanced spatial molecular analysis of post-mortem human brain tissue and controlled animal experiments. The evidence suggests glucosamine crosses the blood-brain barrier and intensifies an already overactive protein sugar‑tagging process, a metabolic change associated with a 25% higher chance of progressing from mild cognitive impairment (MCI) to Alzheimer’s disease and a 25% increase in short-term mortality among patients with established Alzheimer’s disease and related dementias (ADRD).
Key Facts
- The joint supplement dilemma: Glucosamine is widely used over the counter to manage arthritis and joint pain. Because it can cross the blood‑brain barrier, this compound can interact directly with brain metabolism.
- AI analysis of 12 years of records: Investigators applied artificial intelligence to deidentified UF Health records from 2012–2024. They identified that roughly 8% of patients diagnosed with MCI or ADRD reported taking glucosamine.
- 25% higher risk of dementia progression: After adjusting for age, sex and demographic variables, glucosamine use correlated with a 25% greater likelihood of progression from MCI to dementia in the retrospective cohort.
- Increased mortality in established ADRD: Among patients already diagnosed with Alzheimer’s disease and related dementias, glucosamine use was associated with a 25% increase in short‑term mortality risk. This mortality association was not observed in the MCI group, suggesting the diseased brain may be especially vulnerable.
- Overactive protein sugar‑tagging (hyperglycosylation): Using cutting‑edge spatial biomolecule technology, the research team found that Alzheimer’s brains display excessive protein glycosylation—too many sugar tags on proteins—which disrupts protein folding and cellular machinery.
- Validation in animals and human brain tissue:
- Mouse models: Oral glucosamine increased protein glycosylation in genetically modified Alzheimer’s mice and worsened social recognition memory. Chemically blocking the sugar‑tagging enzymes reversed the cognitive deficits in these models.
- Human brain tissue: Post‑mortem samples from the UF Neuromedicine Brain and Tissue Bank showed markedly elevated sugar‑tagging in confirmed Alzheimer’s cases versus non‑diseased controls.
- Implication for treatment: The work reframes metabolic dysfunction—specifically hyperglycosylation—as a potential driver of neurodegeneration and highlights glycan metabolism as a therapeutic target that could complement treatments focused on amyloid‑beta and tau pathology.
Source: University of Florida
Overview: University of Florida neuroscientists report a significant association between glucosamine use and accelerated progression from mild cognitive impairment to Alzheimer’s disease. Their conclusion rests on a multi‑modal approach that includes retrospective electronic health record analysis, spatial metabolomic and glycomic profiling of human brain tissue, and mechanistic studies in mouse models.
Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation at UF’s McKnight Brain Institute, noted the public health implications: with millions living with Alzheimer’s or related dementias, many also use over‑the‑counter supplements that could influence disease progression. The research team specifically investigated whether glucosamine affects disease course and underlying brain metabolism.
The research team, including Yi Guo, Ph.D., and Jiang Bian, Ph.D., used machine learning to extract relevant patterns from deidentified UF Health clinical records covering 2012–2024. They identified 1,896 ADRD patients and 2,750 MCI patients who reported taking glucosamine. Statistical analysis controlling for age, sex and demographics associated glucosamine use with a 25% higher rate of progression from MCI to dementia, and a comparable rise in mortality among ADRD patients.
Sun and colleagues used advanced spatial metabolomics and glycomics to examine molecular changes in brain tissue. Their technology profiles thousands of metabolites and glycans in situ, revealing that Alzheimer’s brains show increased glycan biosynthesis and elevated N‑linked glycosylation. In mice, supplemental glucosamine boosted glycosylation and impaired social memory, while inhibiting glycan biosynthesis improved outcomes, suggesting a causal metabolic mechanism.
Matt Gentry, Ph.D., chair of UF’s Department of Biochemistry and Molecular Biology and co‑author, emphasized that the association between glucosamine and worse outcomes is provocative but not proof of causation. The combined human record data, mouse results and post‑mortem tissue findings create a consistent picture that supports further clinical investigation.
Key Questions Answered:
A: No. The study demonstrates a robust statistical association and provides biological evidence linking glucosamine to hyperglycosylation in vulnerable brains, but it does not establish direct causation. The authors call for clinical trials to validate these findings in humans.
A: Glucosamine can cross the blood‑brain barrier and enter pathways that build complex sugar structures on proteins. In an Alzheimer’s brain where glycan regulation is already impaired, additional substrate may exacerbate excessive sugar‑tagging, disrupting protein function and cellular processes.
A: This study is not a clinical directive. If you use glucosamine—especially if you have MCI, a dementia diagnosis, or strong family history—discuss the risks and benefits with your healthcare provider. Clinicians can weigh joint symptom relief against potential cognitive risk factors and consider alternatives or closer monitoring.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The underlying journal article was reviewed in full by the editorial team.
- Additional context was provided by staff to clarify methods and implications.
About this Alzheimer’s disease research news
Author: Mickie Anderson
Source: UF Health
Contact: Mickie Anderson – UF Health
Image: Image credited to Neuroscience News
Original Research: Open access. “Hyperglycosylation is a metabolic driver of Alzheimer’s disease” by Tara R. Hawkinson et al., published in Nature Metabolism. DOI: 10.1038/s42255-026-01538-4
Abstract
Hyperglycosylation is a metabolic driver of Alzheimer’s disease
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline. While metabolic abnormalities have been observed in AD, their causal role is not fully defined. This study integrates spatial metabolomics, lipidomics and glycomics across transgenic AD mouse models and post‑mortem human samples. Using spatial isotopic tracing of N‑linked glycans, the authors demonstrate a conserved brain hyperglycosylation phenotype driven by increased glycan biosynthesis. Genetic reduction of glycan biosynthetic enzymes improves cognition in AD mice, whereas oral glucosamine worsens outcomes. A retrospective electronic health record analysis links glucosamine supplementation with accelerated AD progression and reduced survival in patients. Collectively, these results identify hyperglycosylation as a pathological driver of AD and position glycan metabolism as an actionable therapeutic target.